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Funding information Jurox Pty Ltd
To demonstrate the bioequivalence of alfaxalone in cyclodextrin (Reference Product) to a formulation of alfaxalone in cyclodextrin also containing the preservatives ethanol, chlorocresol, and benzethonium chloride (Test Product) when administered for the purpose of inducing anesthesia in the cat. Blinded, single-dose, randomized, two-period, twosequence, cross-over bioequivalence study with a 7-day washout period between treatments. Twenty-four (12 neutered males and 12 intact females), healthy, adult cats weighing 4.1±0.9 kg. Cats were administered 5 mg/kg IV of alfaxalone in the Reference or Test Product using a randomized cross-over design. One-milliliter venous blood samples were collected at predetermined time points to 12 hr after drug administration to determine alfaxalone plasma concentration over time. Alfaxalone concentrations were determined by a validated analytical testing method using HPLC-MS/MS. Plasma profiles of alfaxalone concentration against time were analyzed by noncompartmental analysis. The pivotal variables for bioequivalence were AUC last and C max . Equivalence was achieved if the 90% confidence interval for AUC last and C max fell into the asymmetric ±20% interval (0.80-1.25). Physiological variables, quality of anesthesia visual analog scale (VAS) scoring and anesthetic event times were recorded. ANOVA or ANCOVA (single time point), RMANOVA or RMANCOVA (multiple time point) was used for normally distributed data.
GLIMMIX was used for nonnormally distributed data. VAS scores were analyzed as for blood bioequivalence data. Variables were evaluated for safety and assessed at alpha = 0.10. C max and AUC last for Reference and Test Products were statistically bioequivalent. No physiological variables except for a drug by time interaction for respiratory rate differed between treatment groups, and this difference was not clinically relevant. No anesthetic event times or VAS scores for quality of anesthesia were different between treatment groups. Neither formulation caused pain upon injection. The Reference and Test Products are pharmaceutically bioequivalent formulations when administered as a single intravenous administration for the purpose of induction of anesthesia in cats.
| INTRODUCTION
Alfaxalone (3α-hydroxy-5α-pregane-11, 20-dione) is a synthetic neuroactive steroid that interacts and modulates the central gamma aminobutyric acid type A (GABA A ) receptor producing anesthesia and muscle relaxation. Alfaxalone, formulated in 2-hydroxypropyl-β-cyclodextrin (Alfaxan®; Jurox Pty Ltd, Rutherford, NSW, Australia), is registered in multiple countries including the USA and indicated for the induction and maintenance of anesthesia and for the induction of anesthesia followed by an inhalant anesthetic, in cats and dogs. Alfaxalone in 2-hydroxypropyl-β-cylcodextrin (Reference Product) produces a smooth induction, good-quality anesthesia, and rapid recovery in cats due to its rapid redistribution and clearance (Chiu, Robson, Devil, Woodward, & Whittem, 2016; Whittem, Pasloske, Heit, & Ranasinghe, 2008) .
The current formulation does not include a preservative, and the current label in the USA reads "once Alfaxan® has been opened contents should be drawn into sterile syringes; each syringe should be prepared for single patient use only. Unused product should be discarded within 6 hr" (Drug Insert, Alfaxan®, Jurox Inc.). Although other countries such as Australia have more liberal labeling for Alfaxan® after broaching (i.e., 7 days at 4°C), the addition of preservative(s) to the current product would significantly decrease the risk of microbe growth in the vial after broaching if accidental contamination was to occur. In addition, a multidose dose Alfaxan® vial would decrease product wastage in those hospitals that could not use the entire 10 ml content of the current vial within a 6-hr period.
Jurox Pty Ltd has patented (Pasloske, Lau, Richardson, & Willis, 2016 ) a formulation of Alfaxan® containing preservatives that, in vitro, satisfies both European and American Pharmacopeias for antimicrobial efficacy over a 28-day period (EP, 2011; USP, 2011) . The preservatives in the formulation include ethanol (150 mg/ml), chlorocresol (1.0 mg/ml), and benzethonium chloride (0.2 mg/ml). The safety and use of these three preservatives for incorporation into pharmaceuticals has been discussed in the literature (Rowe, Sheskey, & Quinn, 2009 ).
The goal of this pivotal in vivo study was to demonstrate alfaxalone in cyclodextrin containing the three aforementioned preservatives (Test Product) is bioequivalent to the Reference Product, based on the Food and Drug Administration's guidance document for bioequivalence and based on the method of Westlake (FDA's Bioequivalence Guidance, 2006; Westlake, 1988) . In this study, Alfaxan® is the Reference Product, while alfaxalone in 2-hydroxypropyl-β-cyclodextrin plus preservatives is the Test Product. Bioequivalence by definition means that both formulations are equally safe and effective. The second objective of the study was to demonstrate that there was no significant difference in each formulation's effect on physiology, anesthetic event times or quality of anesthesia. were offered food and water once they had fully recovered from the effects of anesthesia.
| MATERIALS AND METHODS

| Animal ethics and husbandry
| Randomization to cohort and treatment group
On Day 1 during randomization and allocation to treatment groups, four cats (2NM and 2F) were removed from the study based on inclusion and exclusion criteria to leave a sample size of 24 cats.
Randomization of cats, blocked by sex, to cohort and treatment groups proceeded using paper ballots. Cats were randomly allocated to treatment groups as per Table 1 . As the logistics of anesthesia and data collection dictated, it was only feasible to treat 12 cats on any given day, each treatment group was randomly divided into two cohorts of six cats each, balanced for sex (3NM, 3F).
Cohort 1 cats were treated on Days 0 and 7, while Cohort 2 cats were treated on Days 1 and 8.
| Test and Reference Products
The following batch numbers and amounts of Test and Reference Products were available for use in the study: Test Product (batch 478/018; 30 × 10 ml vials) and Reference Product (batch G9662; 30 × 10 ml). Both Test and Reference Products were supplied for study with Certificates of Analysis. Storage temperatures of the drugs from receipt (6 September 2013) until last day of treatment (9 October 2013) were from 22.16 to 24.92°C. Test and Reference Products were reconciled by weight. One Test vial and one Reference vial were assigned to each cat. The uniquely identified individual vials were weighed before and after use, and the difference was compared to the calculated total volume administered corrected for weight using specific gravity. In all cases, the actual and intended use weights agreed to within ±0.2 g which was deemed acceptable and accounted for syringe hub loss and syringe accuracy.
T A B L E 1 Study design and treatment groups
Period
Sequence A Sequence B Canada) was applied to the larynx to facilitate intubation, and then a blood sample was collected (see timing below). The cat was endotracheally intubated, and then a blood sample was collected representing the 2-min sample. Immediately afterward, the cat was laid in lateral recumbency on an electric warming blanket and attached to a modified Jackson-Rees nonrebreathing circuit with 100% medical grade oxygen run at 1 L/min.
| Anesthetic monitoring and anesthetic event times
A Subjective quality assessments of anesthetic induction, effectiveness, and recovery were performed by the BCVA. A complete description of how these measurements were performed can be seen in Appendix 1. Cats were fed after recovery, and general health observations were recorded at the time of feeding and the morning after drug administration.
| Blood sample collection and alfaxalone analysis
One-milliliter blood samples for alfaxalone analysis were col- residual standard deviation (RSD) was ± <20% at LLOQ and ± <15%
for all other concentrations. All derived values were reported to three significant figures. AUC last = the area under the curve from time of drug administration to the last quantifiable time point and was calculated with the linear trapezoidal rule (Gibaldi & Perrier, 1982) AUC inf = the area under the curve from time of drug administration to infinity. AUC last + λ z /C last = AUC inf where C last equals the last quantifiable concentration.
| Pharmacokinetic analysis
AUC %extrap = percentage of AUC inf that is due from T last (i.e., time of last quantifiable concentration) to infinity. This was calculated as (AUC last ÷ AUC inf ) × 100%.
V z = volume of distribution based on terminal phase λ z . V z was calculated as: Cl = total body clearance. This parameter was calculated as:
λ z = first-order rate constant associated with the terminal portion of the curve. The estimate λ z was calculated by linear regression on the elimination portion of the curve using a best fit approach where n is the number of data points in the regression and R 2 is the square of the correlation coefficient. For each regression, an adjusted R 2 was computed with:
Plasma alfaxalone concentration values below the LLOQ were assumed to be zero when they occurred before the first value above the LLOQ. The first value below LLOQ after the time of maximum concentration (T max ) was observed and all values after that were excluded from the analysis. Descriptive statistics such as averages, standard deviations, and ranges were tabulated for C max , AUC last , AUC inf , AUC %extrap , V z , Cl, λ z , and t 1∕2 λz . The C max and the T max for alfaxalone for each animal were taken directly from the raw data.
| Statistical analysis
The mean plus standard deviation (+SD) plasma profiles for alfaxalone by formulation were plotted, visually inspected, and are discussed in the Results section. In addition, the method of Westlake (1988) , Visual analog scale data were considered to be continuous in nature. VAS data were treated as for blood level bioequivalence data and analyzed as appropriate for a cross-over study, using a 90% CI for the difference between Reference and Test Products (relative to the mean value of Reference Product) and standard acceptance criteria of ±20%.
Treatment group differences within each variable were compared (i.e., quantitatively, qualitatively, and or statistically) and are discussed with regard to clinical significance. Variables for safety were assessed at alpha = 0.10 and for efficacy (e.g., duration of anesthesia) alpha = 0.05.
| RESULTS
There were multiple variables evaluated in the study. These variables included:
| Physical examination
There were no clinically significant abnormalities noted on physical examinations carried out on Days -7, 0, 1, 7, and 8. There were no clinical signs observed that did not predate the first treatment, and therefore, there was no effect of treatment on physical examination findings.
| Clinical observations and adverse events
Cats remained in good health throughout the study period. The following adverse events were noted: (1) frank blood was noted in the feces of female cat HQY2 on Day 2, 2 days after treatment with Reference
Product. No other observations of frank blood were noted for this cat and fecal texture was unremarkable throughout the study. It is unlikely that this observation was related to treatment, (2) a vomited hairball was noted in the cage of female cat HQZ3 on Day 6, 5 days after treatment with Reference Product. This is a normal albeit sporadic occurrence in the cat colony and was considered unrelated to treatment.
| Body weight
Cats maintained their individual body weights during the study period.
Cats weighed 4.1 ± 0.9 kg (mean ± SD) on Day -7 (acclimation) and 4.1 ± 0.9 kg upon completion of the study (Days 7 and 8).
| Serum biochemistry, hematology, and urinalysis
There were no clinical pathologic abnormalities in acclimation that warranted removal of any cat in the study.
| Physiological variables for anesthesia
Measurements and/or assessments of rectal temperature, pulse rate (PR), heart rate (HR) and rhythm, respiratory rate (RR), mucosa color, capillary refill time (CRT), oxygen saturation of hemoglobin (SpO 2 ), and end tidal CO 2 (ETCO 2 ) were performed on each cat during their anesthetic period. (Table 2) . No cat in the study had a CRT > 2 s, and the mucosa color was always recorded pink and normal. The heart rhythm was never considered abnormal inclusive of sinus arrhythmia. Comparative least square means for the remaining physiological variables are shown in Table 3 . The duration of immediate postinduction apnea (time of first breath-time of endotracheal intubation) was no more than 10 s for any individual cat regardless of treatment.
| Anesthetic event times
There was no difference in effect of formulation on any of the anesthetic event times. Statistical comparison for anesthetic event times is shown in (Table 4 ; p = .34).
| Quality of anesthesia
The sex by product interaction was statistically significant for effectiveness (p = .03), and thus within sex, bioequivalence was evaluated for this outcome (see Table 5 ). The confidence interval for the difference between the two products, relative to the Reference Product mean value in females and males, was −17.57% (lower) and 
| Pharmacokinetics
Superimposition of the mean alfaxalone versus time profiles of Reference Product and Test Product in Figure 1 shows that the formulations are the same. Table 6 shows the mean (±SD) data for the pharmacokinetic parameters for the Reference Product and the Test
Product. The results show that the parameters are similar between the two groups and the arithmetic means for both C max and AUC last are virtually the same for the two formulations (n = 24 for each treatment). Table 7 shows the result of the bioequivalence calculation. The data show that Reference Product and Test product are bioequivalent as for each of the primary variables C max and AUC last the 90% confidence interval fell completely within the acceptance region of 80-125% for back-transformed data.
| DISCUSSION
This study compared the pharmacokinetics and pharmacodynamics of a single 5 mg/kg IV dose of alfaxalone in 2-hydroxypropyl-β-cyclodextrin Once the formulation meets the antimicrobial killing requirements for the parenteral formulation, in this case the Test Product, it still has to be tested for safety in the target species. Cats are a unique species with respect to metabolism having a deficiency in the phase II glucuronidation pathway necessary for the metabolism and subsequent clearance of toxic compounds including benzoic acid (Baggot, 1977; Bridges, French, Smith, & Williams, 1970) ; therefore, it can never be assumed that added preservatives or co-solvents in an injectable formulation are benign to cats. There is little information on the species-specific metabolism of chlorocresol and benzethonium chloride in cats. Chlorocresol is a water-soluble hydroxylated phenol that is metabolized by conjugation with both glucuronate and sulfate and is excreted in the urine, mainly as a conjugate, with little chlorocresol being excreted unchanged (Rowe et al., 2009 There were no adverse events observed for either product at the clinically recommended dosage of alfaxalone administered in this study. However, alfaxalone has a label claim for both the induction and maintenance of anesthesia through repeated injections in the USA, and therefore, a reasonable question about the Test Product formulation is: Are there any safety concerns when Test Product is administered repeatedly or by infusion during the same anesthetic session? Recently, the RD0327 formulation has been administered as an infusion to cats over an extended period. Pypendop et al. have infused the RD0327 formulation in cats for 240 min on two occasions (Pypendop, Ranasinghe, & Pasloske, 2017a,b) . In both studies, all cats survived and there were no adverse events. In addition, if the maximum induction and maintenance doses of the Reference Product observed in an unpremedicated cat, as per the US label, are used to mock up an anesthetic scenario of a Test Product induction plus three maintenance doses (i.e., 9.7 mg/kg + (3*1.5 mg/kg), the volume per kg of body weight of the Test Product administered to a cat would be 1.42 ml/kg. This figure in combination with the LD50 of each of the preservatives could then give us a better understanding of the margin of safety of the Test Product in the cat. Table 8 shows the margin of safety of each of the three preservatives using mouse LD50 data from the literature (Rowe et al., 2009) . For chlorocresol, benzethonium Cl, and ethanol, the margins of safety are 49×, 106×, and 9×, respectively, giving reassurance that the formulation is safe. To further place the margin of safety into perspective for ethanol, a calculation for the amount of ethanol to treat ethylene glycol intoxication can be made. The dosing regimen suggested is a 20% solution given at 5 ml/ kg IV every 6 hr for 5 treatments then every 8 hr for four additional treatments (Plumb, 2011) . This equates to 9,000 mg/kg over 62 hr or 145 mg kg
. This is 42× the amount of ethanol (i.e., 213 mg/ kg) shown in Table 8 and is still considered to be safe for therapeutic purposes. Finally, the end user of the Test Product formulation can also be confident of product safety if other registered formulations in the veterinary industry contain the same preservatives. Table 9 shows examples of regulatory-approved commercial formulations currently administered intravenously or subcutaneously to cats containing chlorocresol, benzethonium chloride, or ethanol.
In conclusion, this pharmacokinetic and pharmacodynamic bioequivalence study has demonstrated that the FDA-registered and commercially available Alfaxan® intravenous injectable anesthetic for use in dogs and cats is bioequivalent to a newly patented Alfaxan® formulation containing a preservative system when administered as a single dose at the approved rate of 5 mg/kg body weight in the cat. Therefore, T A B L E 7 Summary of statistical analysis of plasma alfaxalone-evaluation of bioequivalence for Reference Product and Test Product veterinarians and technicians can interchange the formulations without observing any change in induction for anesthetic efficacy or safety.
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